中国药物警戒 ›› 2021, Vol. 18 ›› Issue (5): 489-491.
DOI: 10.19803/j.1672-8629.2021.05.18

• 安全与合理用药 • 上一篇    下一篇

注射用硫酸多粘菌素B致皮肤色素沉着1例分析

陈建寿1, 王敏2,*   

  1. 1儋州市人民医院,海南 儋州 571700;
    2海南省人民医院,海南医学院附属海南医院,海南 海口 570100
  • 收稿日期:2019-12-10 出版日期:2021-05-15 发布日期:2021-05-12
  • 通讯作者: *王敏,女,硕士,副主任药师,临床药学。E-mail:15799077523@163.com
  • 作者简介:陈建寿,男,本科,主管药师,临床药学。
  • 基金资助:
    海南省科技厅重点研发项目(ZDYF2019141)

One Case of Skin Pigmentation Induced by Polymyxin B for Injection

CHEN Jianshou1, WANG Min2,*   

  1. 1Danzhou People's Hospital, Danzhou Hainan 571700, China;
    2Hainan General Hospital, Hainan Hospital Affiliated to Hainan Medical College, Haikou Hainan 570100, China
  • Received:2019-12-10 Online:2021-05-15 Published:2021-05-12

摘要: 目的 分析注射用硫酸多粘菌素B致皮肤色素沉着的可能因素,促进临床合理用药。方法 分析1例多粘菌素B致皮肤色素沉着患者的诊疗经过,结合文献检索,探讨诱发皮肤色素沉着的机制及应对措施。结果 患者静脉使用多粘菌素B后第14天观察到头、颈部皮肤出现色素沉着,考虑合并用药西罗莫司血药浓度蓄积所致,将西罗莫司剂量减半并监测该药血药浓度,发现西罗莫司在有效血药浓度范围内。第30天患者感染得到控制,停用多粘菌素B,此时患者全身皮肤呈深棕褐色,随访5个月全身皮肤较前明显转淡,但未恢复常态。结论 多粘菌素B引起的皮肤色素沉着应选择替代治疗方案,如确实需要继续使用应避免同时或相继使用神经毒性或肾毒性药物,并在治疗期间监测肾功能和多粘菌素B血药水平。

关键词: 多粘菌素B, 皮肤色素沉着, 药物相关副作用

Abstract: Objective To analyze the possible factors of skin pigmentation caused by polymyxin B for injection and promote the rational use of drugs in clinic. Methods The diagnosis and treatment of a case of skin pigmentation caused by polymyxin B were analyzed and combined with literature search to explore the mechanism and countermeasures of skin pigmentation induced. Results On the 14th day after the patient's intravenous administration of polymyxin B, the patient's head and neck skin were observed to be pigmented. Considering the combination of sirolimus blood concentration accumulation, reduce the sirolimus dose by half and monitor the drug Blood concentration. It was found that sirolimus was within the effective blood concentration range. The infection was controlled on the 30th day, and polymyxin B was discontinued. At this time, the patient's body skin was dark brown, and the patient's body skin was followed up for 5 months. Significantly weaker than before, but did not return to normal. Conclusion Alternative treatment options should be selected for polymyxin B-induced skin pigmentation. If continued use is warranted, simultaneous or sequential use of neurotoxic or nephrotoxic drugs should be avoided, and renal function and polymyxin B blood levels should be monitored during treatment.

Key words: polymyxin B, skin pigmentation, drug-related side effects

中图分类号: